Orchid Cellmark to Bloom – Analyst Blog
Source: http://www.zacks.com/stock/news/16656/Orchid+Cellmark+to+Bloom+-+Analyst+BlogPosted on Tuesday, January 6th, 2009 | In Stocks to Watch
Orchid Cellmark Inc. (ORCH) is a leading provider of DNA testing services for forensic, human identity and agricultural applications in the U.S. and the U.K. The company is also the world’s largest provider of “scrapie susceptibility genotyping.”
The company expanded its reach in the U.S. with the acquisition of ReliaGene in October 2007. The company is now leveraging its expertise in DNA testing to enter into new markets like pork traceability, immigration testing and security applications.
Orchid Cellmark has won a major part of the mega-tender in the U.K., which will result in annual revenues of $10 million for the next 3 years. As such, we maintain our Buy rating on the stock with a revised target price of $2.50.
Maharathi Basu contributed to this report.
Read the full analyst report on ORCH
“ORCH” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
agricultural applications;, Blog, genotyping, Orchid Cellmark Inc.;, ReliaGene;, scrapie;, Security Applications, Stocks to Watch, United Kingdom, United States, USD, Zacks Market Commentaries
![]() About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |



